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Abstract
Here we describe a collaboration between industry, the National Health Service (NHS) and
academia that sought to demonstrate how early understanding of both pharmacology and
genomics can improve strategies for the development of precision medicines. Diseased tis-
sue ethically acquired from patients suffering from chronic obstructive pulmonary disease
(COPD), was used to investigate inter-patient variability in drug efficacy using ex vivo orga-
nocultures of fresh lung tissue as the test system. The reduction in inflammatory cytokines
in the presence of various test drugs was used as the measure of drug efficacy and the indi-
vidual patient responses were then matched against genotype and microRNA profiles in an
attempt to identify unique predictors of drug responsiveness. Our findings suggest that
genetic variation in CYP2E1 and SMAD3 genes may partly explain the observed variation in
drug response.
Introduction
It is well recognised that one size does not fit all when it comes to the treatment of many dis-
eases. Getting the right drug to the right patient at the right dose has become the focus of preci-
sion medicine, which provides hope that patients may receive the most appropriate treatment
sooner, improving their quality of life and reducing the support required from health care sys-
tems and wider society [1]. Health economists are recognising the potential of precision medi-
cine and are beginning to apply the concept to their research [2].
PLOS ONE | https://doi.org/10.1371/journal.pone.0226564 December 20, 2019 1 / 15
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Cowan K, Macluskie G, Finch M, Palmer
CNA, Hair J, Bylesjo M, et al. (2019) Application of
pharmacogenomics and bioinformatics to
exemplify the utility of human ex vivo
organoculture models in the field of precision
medicine. PLoS ONE 14(12): e0226564. https://
doi.org/10.1371/journal.pone.0226564
Editor: Erika Cecchin, Centro di Riferimento
Oncologico, ITALY
Received: May 8, 2019
Accepted: November 28, 2019
Published: December 20, 2019
Copyright: © 2019 Cowan et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The data can be
found in the Figshare repository and has the
following reserved DOI: 10.6084/m9.figshare.
10101371.
Funding: Funding for this study was via a project
grant from Stratified Medicines Scotland
Innovation Centre (SMS-IC, https://www.stratmed.
co.uk/), provided to REPROCELL Europe Ltd
(https://www.reprocell.com/) and the University of
Dundee (https://www.dundee.ac.uk/). REPROCELL
The genomics revolution has underpinned much of this research. As the cost of gene
sequencing has fallen, the ability to rapidly identify an individual’s genotype as part of routine
health care has become possible. For precision medicines to be developed however, genomics
must be linked to pharmacology, thereby relating the individuals genotype to the effectiveness,
potency and tolerability of a drug. It is through pharmacogenomics that truly personalised
therapies may emerge, yet the link between genomics and pharmacology may not be properly
understood until expensive and risky clinical trials are conducted.
Here we describe a collaboration between industry, the National Health Service (NHS) and
academia that sought to demonstrate how an early understanding of both pharmacology and
genomics can improve strategies for the development of precision medicines. By using the lat-
est pharmacology techniques in human fresh tissues donated by the target patient population,
combined with genomics and clinical metadata associated with each individual, an improved
understanding of the link between genetics and inter-individual drug responses emerges. A
diagrammatic representation of this collaboration has been provided (Fig 1) to detail the inter-
action between each collaborator and the different data streams.
An early understanding of patient stratification during drug discovery is becoming increas-
ingly important. Selection and optimisation of candidate drugs for well-defined patient subsets
has the potential to help in the design of more rapid, targeted clinical trials.
A key incentive to better understand pharmacogenomics during the drug discovery process
is the rapid increase in drug development costs. The most recent estimates of the out-of-pocket
costs (i.e. excluding capital costs) of drug development are in the region of $890 million [3],
with approximately 70% of the costs incurred during clinical development. The most common
cause of failure is poor efficacy at phase II or III [3–6], which is in part attributed to ‘all comer’
clinical trials of entire patient populations that are likely to include both ‘responders’ and
‘non-responders’ to the drug being tested. Precision medicine aims to improve the prediction
of clinical efficacy by selecting for clinical trials only those patient sub-populations likely to
gain clear benefit. This approach also benefits patients classed as ‘non-responders’ for a drug
treatment as it opens up clear market opportunities for drug developers to develop effective
treatments for these populations. Predictions of optimal patient sub-populations are however
dependent on the quality of the information available to stratify these sub-populations before a
Fig 1. Diagram describing the interaction between each collaborator and the different data streams.
https://doi.org/10.1371/journal.pone.0226564.g001
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drug enters clinical development. Preclinical tests of drug effects must therefore closely reflect
the intended patient population(s).
The most desired traits in preclinical models are “physiological relevance” and the ability to
translate findings to likely clinical responses [4,6–8]. Obtaining a high level of confidence in
the biological role of the drug target in human disease during preclinical development has
been shown to be was a good predictor of successful clinical trials [6]. Human fresh tissues and
complex human 3D tissue models that reflect the biology of disease are therefore increasingly
being used by Pharma to improve the prediction of efficacy in clinical trials [7,9,10]. In this
study human lung tissue from diseased patients was used to further increase confidence in the
‘physiological relevance’ of the test system. Using human tissue based systems at a preclinical
stage also provides the opportunity to allow the discovery of biomarkers that can be leveraged
in the clinic, either as a marker of drug response or as a patient stratification marker. Although
the data between different patients can be variable, this is viewed as an opportunity for an early
understanding of the extent and causes of inter-patient variation in drug response.
Chronic Obstructive Pulmonary Disease (COPD) is a major health problem and is an
example of a complex condition, with many clinical phenotypes. Many patients receive mini-
mal clinical benefit from common medications, most likely due to the combination of varia-
tions in disease subtype and genotype.
In this project, diseased tissue ethically acquired from patients suffering from COPD, was
used to investigate inter-patient variability in drug efficacy using ex vivo organocultures of
fresh lung tissue as the test system. To investigate the level of patient stratification that can be
achieved from a preclinical study, the commonly used ‘all comers’ clinical trial patient recruit-
ment policy [11] was mimicked with no donor inclusion criteria other than a clinical diagnosis
of COPD applied.
In order to assess patient variation in responsiveness to both ‘standard of care’ and combi-
nation ‘standard of care’ therapies, the reduction in inflammatory cytokines in the presence of
the test drugs was used as the measure of drug efficacy.
Included in this study were 3 different ‘standard of care’ medications that reflect what is
currently available to patients and what is routinely prescribed to those suffering with differing
severities and phenotypes of COPD. Roflumilast is a selective, long-acting inhibitor of the
enzyme phosphodiesterase-4 (PDE-4) commonly used to treat COPD patients that present
with chronic cough. It has been shown to provide clinical benefit however has been associated
with multiple adverse events [12]. Fluticasone is commonly an inhaled corticosteroid used in
the treatment of asthma and COPD, however variation in treatment efficacy has been reported
[13]. Formoterol is a long-acting β2 adrenoceptor agonist, intended for use as a bronchodilator
in the management of COPD. The individual patient ex vivo lung tissue responses were then
matched against genotype, patient demographic and microRNA profiles to identify unique
predictors of drug responsiveness and demonstrate the combined power of pharmacology and
genomics during preclinical development.
Materials and methods
Ex vivo organoculture—REPROCELL
Lung parenchyma tissue was ethically obtained from 25 patients, clinically diagnosed with
COPD who were undergoing therapeutic resection surgery for cancer or COPD. Residual tis-
sue from the resection surgery, which was not required for clinical pathology, was acquired
from NHS Research Scotland Biorepository Network and also through the REPROCELL tissue
network. The West of Scotland Research Ethics Committee (12/ws/0069) granted approval for
this study, and patients provided written consent complying with the declaration of Helsinki.
Pharmacogenomics and bioinformatics in the field of precision medicine. Human ex vivo organoculture
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Two biopsies (5 mm3) were immediately processed in RNAlater, prior to storage and subse-
quent RNA and DNA extraction. The remaining biopsies (5 mm3) were subjected to the fol-
lowing culture protocol.
Culture medium was prepared by supplementing RPMI 1640 culture medium with the fol-
lowing constituents: gentamicin (100 μg/mL), amphotericin B (0.625 μg/mL), FBS (0.5%), reti-
nyl acetate (0.1 μg/mL), bovine insulin (1 μg/mL) and nystatin (1 μg/mL).
Following an overnight rest period in culture medium, lung biopsies (2 per well) were cul-
tured in a humidified incubator (37 ˚C, 5% CO2), in culture media fortified with either roflu-
milast (100 nM), fluticasone (1 μM), formoterol (10 nM), roflumilast (100 nM) + fluticasone
(1 μM), formoterol (10 nM) + roflumilast (100 nM) or the DMSO vehicle control. LPS (100
ng/mL) was added to all wells, to mimic the effects of a bacterial exacerbation of COPD and
therefore boost biopsy inflammatory cytokine release. Each experimental condition was per-
formed in duplicate culture wells.
At 24 hours post-incubation start, the supernatant from each well was collected, protease
inhibitor added, and the samples stored at -80 ˚C prior to analysis for TNFα content.
Levels of TNFα (pg/mL) were measured in culture supernatants using a magnetic bead-
based assay for the Luminex MAGPIX platform. Each culture supernatant sample was ana-
lysed in duplicate and the mean value used in downstream analyses.
RNA, DNA extraction—Sistemic
DNA was extracted from approximately 10 mg tissue using the PureLink™ Genomic DNA
Mini Kit. DNA quality control was performed using the Agilent 2200 TapeStation and the
Genomic DNA ScreenTape kit to determine the DNA integrity number (DIN).
RNA was extracted from approximately 10 mg of tissue. Tissue was homogenised and total
RNA was then extracted using the miRCURY RNA Isolation Kit–Cell & Plant. Absorbance
ratios at 260/280 nM and 260/230 nM were determined as indicators of sample yield and
purity. Further RNA quality control was performed using the Agilent 2200 TapeStation and
the ScreenTape R6K kit to determine the RNA integrity number (RIN).
miRNA analysis—Sistemic
MicroRNA (miRNA) expression levels were measured using the Agilent miRNA platform,
specifically; Agilent’s SurePrint G3 Human v16 microRNA 8x60K microarray slides, miRBase
version 16.0.
Exome sequencing—SMS-IC
Targeted next generation sequencing libraries were prepared using the Ion Ampliseq™ Exome
RDY Kit and DNA isolated from baseline lung biopsies. Multiplexed PCR was performed to
produce barcoded libraries, using 100 ng of input DNA per sample and 10 amplification
cycles. The Ion AmpliSeq™ Library Kit Plus and IonXpress™ Barcode Adapters were used in
library preparation, according to the manufacturer’s instructions. Final library concentrations
were determined by quantitative real time PCR using the Ion Library TaqMan™ Quantitation
Kit. Libraries were diluted to 100 pM, and 2 libraries were subsequently pooled in equal
amounts for templating on the Ion OneTouch™ 2 System, using the Ion PI™ Hi-Q™ OT2 200
kit. The Ion Proton™ NGS platform was used for sequencing of multiplexed templated librar-
ies, using the Ion PI™ Hi-Q™ Sequencing 200 Kit and the Ion PI™ Chip Kit v3, according to the
manufacturer’s instructions.
Pharmacogenomics and bioinformatics in the field of precision medicine. Human ex vivo organoculture
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Raw data storage—Aridhia
Raw data (ex vivo organoculture TNFα levels, miRNA expression profiles and exome sequenc-
ing data) was uploaded to a secure workspace (AnalytiXagility) in Aridhia’s digital research
platform.
Anonymised, patient demographic data obtained from NHS Research Scotland Bioreposi-
tory Network or the REPROCELL tissue network was also uploaded to the collaboration’s
AnalytiXagility workspace. Data could then be accessed and analysed in a secure manner by
authorised users.
Fios Genomics accessed data held in the AnalytiXagility research workspace to provide bio-
informatic analyses. Each dataset was analysed individually and combined to determine any
significant correlations between patient demographic data, genetic polymorphisms and/or
miRNA profiles and the observed organoculture assay response.
All the data sets that were used in the bioinformatic analyses have been fully anonymised
and may be accessed via the following 10.6084/m9.figshare.10101371.
Organoculture bioinformatic analysis—Fios Genomics
TNFα levels determined for each patient sample in the organoculture assay, were subjected to
quality control metrics from the ArrayQualityMetrics package in Bioconductor [14]. Assays
were scored on the basis of the following parameters: maplot; boxplot and heatmap. An indi-
vidual patient sample was classified as an outlier if two or more of the parameters were not
met.
TNFα levels (pg/mL) for each experimental condition were normalised using log2 ratios
against the DMSO vehicle control. Relative levels of TNFα were then visualised using bar
charts, density plots and correlation plots within R software. The aim was to identify sub-
groups of patients that displayed a good response to one or more of the organoculture test con-
ditions and subgroups of patients that displayed a poor response. Response to a test condition
was defined as a reduction in TNFα levels compared to the DMSO control test condition.
Patients were then categorised as being a high responder to treatment or a low responder to
treatment for use in subsequent bioinformatic analyses.
Defined patient demographic parameters and organoculture assay response were assessed
using pair-wise univariate associations between all combinations of defined parameters. Asso-
ciations between categorical parameters were assessed using a chi-squared test; associations
between one categorical and one continuous parameter were assessed using analysis of vari-
ance (ANOVA); associations between two continuous parameters were assessed using a Spear-
man correlation test.
Exome sequence bioinformatic analysis—Fios Genomics
Torrent Mapping Alignment Program was used to provide IonTorrent AmpliSeq exome
sequencing data for each patient. Data was provided as a BAM file aligned to genome reference
GRCh37. Genotypes called with Torrent Variant Caller were provided as per sample VCF files.
Single nucleotide polymorphisms (SNPs) from the VCF files were merged into a multi-sam-
ple VCF and BAM files were used to set missing genotypes to homozygous reference if the
read-depth of the SNP in a particular sample was less than 30. VCF files were then filtered to
remove low quality SNPs.
Exploratory analysis was first performed by producing principal component analysis plots,
using the SNPRrelate R software package. Hierarchical clustering of the data measured dissim-
ilarity between patient exome data [15].
Pharmacogenomics and bioinformatics in the field of precision medicine. Human ex vivo organoculture
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The genotype for all SNPs identified from the VCF file was tested for association with the
organoculture assay response, this was performed using fisher-exact tests of association within
the PLINK analysis toolkit [16]. Identified SNPs included those that were known to be related
to genes of interest and also novel, undescribed SNPs.
Genes of interest were identified due to a literature association with the pathology of COPD
and/or as being associated with lung metabolism and/or genes that may be associated with
clinical response to standard of care treatments.
Identified SNPs were also cross-referenced with SNPs listed in the Genome Wide Associa-
tion Studies (GWAS) Catalog to determine if any SNP had been previously reported in a human
GWAS study and, if so, it was determined if the reported association was relevant to this study.
miRNA bioinformatic analysis—Fios Genomics
Quality control was assessed using the quality control metrics from the ArrayQualityMetrics
package in Bioconductor [14] as for the organoculture assay data above.
Confounding associations between defined patient demographic parameters and miRNA
expression array data were assessed using pair-wise univariate associations between all combi-
nations of defined parameters. Associations between categorical parameters were assessed
using a chi-squared test; associations between one categorical and one continuous parameter
were assessed using analysis of variance (ANOVA); associations between two continuous
parameters were assessed using a Spearman correlation test.
Data was normalised using quantile normalisation which produces expression measures in
a log base 2 format. Array batch effects due to processing of microarray data in two separate
batches were corrected using the ComBat method [17].
Statistical comparisons were performed to determine if specific miRNAs were associated
with organoculture assay response: the null hypothesis being that no specific differences in
miRNA expression could be detected in patients that responded well in the organoculture
assay compared with patients that did not respond. Linear modelling, empirical Bayesian anal-
ysis and p-value adjustment for multiple testing (Benjamini-Hochberg) was performed using
the Bioconductor Limma software package [14].
miRNAs were annotated based on their experimentally verified target genes from miRTar-
Base [18]. miRNAs that displayed significant differential expression (uncorrected p<0.05),
were analysed for enrichment of target gene KEGG (Kyoto Encyclopaedia of Genes and
Genomes) pathway membership using a hypergeometric test. Upregulation and downregula-
tion of genes were analysed separately.
In the same way, miRNA target genes were analysed for enrichment of gene ontology terms.
Bioinformatic analyses integration—Fios Genomics & University of
Dundee
Integration of patient demographic, TNFα organoculture response, exome sequence and
miRNA expression data.
Congruence analysis was performed by evaluating the level of overlap between all data sets.
Calculations of significant overlaps were based on a hypergeometric test.
Results
Ex vivo organoculture
All patient samples passed quality control analysis as described previously. The majority of
COPD patient lung samples responded to treatment with fluticasone, roflumilast or
Pharmacogenomics and bioinformatics in the field of precision medicine. Human ex vivo organoculture
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combination therapy. This was observed as a reduction in the level of TNFα released from
the biopsies into the culture media (Fig 2). Different levels of response were however
observed between patients and ranged from modest to a marked reduction in TNFα in the
supernatant.
Fluticasone alone or in combination with roflumilast generated the greatest inhibition of
TNFα release. When the effects of monotherapy and combined therapy were compared, there
was no difference in the mean reduction in TNFα levels; however, combined therapy may
have resulted in a bimodal pattern of drug response across the patient sample group (Fig 3).
Based on this density plot, patients were dichotomised into "High responders" and "Low
responders" based on the average values. Twelve patient samples were categorised as being
high responders and thirteen as low responders to the roflumilast plus fluticasone treatment.
Principal component analysis [19] was conducted to explore the relationship between the
many variables (Fig 4).
Association analysis of patient demographic parameters and response to roflumilast plus
fluticasone showed that the response was not influenced by any of the patient demographic
factors such as gender or age. Treatment response was noted to be significantly associated with
the first principal component; this indicates that response to roflumilast plus fluticasone is the
primary trend in the data.
A strong association was observed between ethnicity and supplier region, this is however
believed to be the result of one sample that was acquired from a geographical region distinct
from all other regions. The ethnicity of this patient was also not replicated in any other sample.
Classes of chronic medication appear to be strongly related to each other; this is not surpris-
ing as the standard of care treatment for COPD includes combinations of the classes of drugs
identified. Chronic medication appeared not to influence patient response to roflumilast plus
fluticasone in the organoculture assay and is therefore not thought to be responsible for the
variation in response between patients.
Fig 2. Graphs showing the effects of test articles on TNFα release from stimulated human lung parenchyma biopsies. n = 25
donors, all diagnosed with COPD. Data is displayed as a percentage of the corresponding DMSO control group in both graphs. A: Bar
graph depicting mean + SEM TNFα release. B: Scatter graph depicting individual patient (dots) and median (thick black line) TNFα
release.
https://doi.org/10.1371/journal.pone.0226564.g002
Pharmacogenomics and bioinformatics in the field of precision medicine. Human ex vivo organoculture
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Exome sequence analysis
Preliminary analysis showed that all samples were of good quality, with between 38 and 57 mil-
lion reads; this resulted in 36,702 to 38,065 SNPs being identified per patient sample. Merging
and filtering of VCF files for high quality SNPs resulted in 101,557 SNPs being retained for the
exome wide association analysis. Hierarchical clustering and principal component analysis
identified two patient samples as outliers. One of the outlying samples is described above and
is thought to have resulted in a slight association with ethnicity and supplier region. There is
no explanation for the second outlying sample, however as the two samples did not show any
quality-related discrepancies both samples were included in downstream analysis.
Fisher’s exact test, performed in the PLINK toolkit, showed that no genotypes correspond-
ing with the identified SNPs were significantly associated with the organoculture response.
However, to allow a very tentative interpretation of the results, and taking into account the low
number of patients studied, an uncorrected p-value of<0.001 was chosen. With this approach
a total of 30 SNPs, corresponding to 23 genes, were found to correlate with the level of TNFα
release upon treatment with roflumilast plus fluticasone. A number of these genes have
reported associations with COPD or other pulmonary diseases and include; CYP2E1 [20],
HEY1 [21], SMAD3 [22], BARD1 [23] and FOXP1 [24].
Fig 3. Visualisation of patient-to-patient changes in the relative levels of TNFα after combination treatment of
roflumilast (100 nM) and fluticasone (1 μM). The density plot shows histogram bin counts (number of times a value falls
within a given bin) as white bars as well as a smooth density in pink of the log2 ratios of TNFα release from biopsies treated
with roflumilast plus fluticasone, relative to those treated with DMSO (which also includes LPS and the vehicle control),
across all 25 patients. The average level in the treated biopsies is denoted by a blue dashed vertical line and the red dashed line
denotes zero as this is the average level in control biopsies.
https://doi.org/10.1371/journal.pone.0226564.g003
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CYP2E1 is an inducible drug metabolising enzyme expressed in human lung tissue and has
been implicated in pathological oxidative stress [20,25]. Expression of CYP2E1 SNPs including
rs3737034 and rs2249695 were shown to correlate with patient organoculture response. The
significance level was however borderline as determined in the bioinformatic analysis (p
0.008/0.01).
Our findings suggest that genetic variation in the cytochrome p450 enzyme (CYP2E1)
gene, namely SNP (rs2249695), may partly explain the observed variation in drug response.
Biopsies from patients who had at least one copy of the reference allele for this SNP generally
responded better to roflumilast and fluticasone co-treatment. Mean TNFα release (Fig 5) was
inhibited by 77.6% (homozygous reference genotype (TT)) and by 50.74% (homozygous alter-
native genotype (CC)). Levels of inhibition between these two genotypes were found to be sig-
nificantly different with a p value of 0.02 (unpaired, two-tailed t-test). The homozygous
reference haplotype has been associated with low CYP2E1 expression [20].
Genetic variation in mothers against decapentaplegic homolog 3 (SMAD3) gene was also
found to relate to patient organoculture response. Mean TNFα release (Fig 6) was inhibited by
66% (homozygous alternative genotype (GG)) and by 39% (heterozygous genotype). Levels of
inhibition between these two genotypes were found to be significantly different with a p value
of 0.0054 (unpaired, two-tailed t-test). Only two patient samples were found to have the
Fig 4. Heat map showing the results of patient demographic correlation with TNFα release from stimulated
human lung parenchyma biopsies following roflumilast and fluticasone co-treatment. Each parameter is assessed
in relation to each other, the principal components (PC) driving variation in the data and to the organoculture assay
response. Each area within the heatmap denote a p-value of association between pairs of variables from statistical tests.
The statistical tests utilised depends on the property of the factors: for an association between two categorical factors, a
chi-squared test was used. For an association between a categorical and a continuous factor, ANOVA was used. For an
association between two continuous factors, a Spearman correlation test was used. In all cases, the resulting p-value
was transformed as -log10(p) before being visualised in the confounding factors heatmap.
https://doi.org/10.1371/journal.pone.0226564.g004
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homozygous reference haplotype (AA) and mean TNFα release was inhibited by 54% in this
group of patient samples. This level of inhibition was not significantly different to the homozy-
gous alternative genotype or the heterozygous genotype.
The GWAS catalogue contains 624 SNPs identified in the exome sequence analysis, 4 of
these SNPs are annotated in the catalogue as being associated with COPD; 6 have been associ-
ated with asthma and 4 are related to other pulmonary conditions. It was however found that
Fig 5. Graphs showing the relationship between CYP2E1 SNP rs2249695 genotype and TNFα release from stimulated
human lung parenchyma biopsies following roflumilast and fluticasone co-treatment. Data is displayed as a percentage of the
corresponding DMSO control group. Asterisks indicate significant differences (p< 0.05, for one, p< 0.01 for two and p< 0.001
for three). A: Box and whiskers graph depicting TNFα release. The 25th and 75th percentiles of each group are represented by
the box with the minimum and maximum values represented by bars, the line within each box denotes the median value. B: Bar
graph depicting mean + SEM TNFα release.
https://doi.org/10.1371/journal.pone.0226564.g005
Fig 6. Graphs showing the relationship between SMAD3 SNP rs1065080 genotype and TNFα release from stimulated
human lung parenchyma biopsies following roflumilast and fluticasone co-treatment. Data is displayed as a percentage of the
corresponding DMSO control group. Asterisks indicate significant differences (p< 0.05, for one, p< 0.01 for two and P< 0.001
for three). A: Box and whiskers graph depicting TNFα release. The 25th and 75th percentiles of each group are represented by
the box with the minimum and maximum values represented by bars, the line within each box denotes the median value. B: Bar
graph depicting mean + SEM TNFα release.
https://doi.org/10.1371/journal.pone.0226564.g006
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no SNPs annotated in the catalogue correlated to roflumilast plus fluticasone response in this
study.
miRNA analysis
RNA quality control analysis showed that isolated RNA was of high purity, 260/280 ratios ran-
ged from 1.8 to 2.0 and RNA integrity scores ranged from 5.8 to 7.8.
All patient samples, except one, passed Agilent miRNA array quality control analysis with a
rating of good to excellent. The remaining sample was flagged for evaluation and removed
from subsequent bioinformatic analysis.
Statistical analysis showed that there were no specific differences in miRNA expression
detected in patients that responded well in the organoculture assay compared with patients
that did not respond. This analysis was performed using a p-value that had been adjusted
for multiple statistical testing. For the purposes of this exemplar study, a relaxed p-value
(uncorrected p <0.05) was subsequently applied. At this threshold, 181 miRNAs, mapping
to 636 genes, were found to be differentially expressed in COPD patient samples that were
high responders to roflumilast plus fluticasone treatment compared with samples that
showed a poor response. 86 miRNAs were found to be upregulated, correlating with 47
KEGG pathways that reached statistical significance. This Enrichment analysis highlighted
KEGG pathways associated with TGF-β signalling, synaptic function and fatty acid
metabolism.
95 miRNAs were found to be down regulated correlating with 4 KEGG pathways that
reached statistical significance. This Enrichment analysis highlighted KEGG pathways associ-
ated with long-term depression and serotonergic and GABAergic synaptic function.
1,610 GO terms were significantly associated with up-regulated miRNAs and found to be
significantly enriched for pathways associated with cell ageing, specifically telomerase activity.
Pathways involved in synaptic activity and T cell differentiation were also found to be
upregulated.
310 GO terms were significantly associated with down-regulated miRNAs and found to be
significantly enriched for pathways associated with B cell receptor activity and TGF-β
production.
As discussed, bioinformatic analysis identified 30 SNPs corresponding to 23 genes
(p<0.001) and 181 miRNAs (mapping to 636 genes, p<0.05) as being related to organocul-
ture response. With further relaxation of the exome analysis p value to 0.01, congruence analy-
sis found that a total of 10 genes overlapped between the exome sequence and miRNA
expression data (Fig 7). This overlap is higher than would be expected by chance. Overlapping
genes are NTN4, IGF1R, SMAD3, EGFR, MCL1, FBN1, FGA, APP, MYO10 and IRAK3. Six
overlapping genes were subject to upregulation (SMAD3, EGFR, MCL1, FBN1, FGA & APP)
however the remaining 4 overlapping genes did not agree with respect to overlap direction.
Absolute minor allele frequencies from the exome sequence analysis were used as a surrogate
for fold changes in the SNP data. No strong correlations were found between absolute minor
allele frequencies and miRNA log fold-changes. KEGG and GO enrichment analysis of the
overlapping genes did not identify any common pathways or processes.
Discussion
This study aimed to demonstrate the potential of research that combines preclinical functional
characterisation of drug efficacy and inter-patient variation in drug responses, with state-of-
the-art genomics and bioinformatics, as a new way to model precision medicine strategies at
the early stages of drug development.
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COPD is a highly complex condition with many clinical phenotypes. As an exemplar proj-
ect, the number of patients was relatively low and findings are therefore tentative, however,
this study was also designed to explore the potential for such projects during non-clinical drug
development, where budgets are limited and projects exploring hundreds of patients may be
too costly.
Nonetheless, clear variations in drug effectiveness were observed between patients and our
preliminary experimental findings suggest that genetic polymorphisms in COPD patients may
be linked to variation in response to the combination anti-inflammatory treatment, roflumilast
plus fluticasone. A haplotype associated with low CYP2E1 expression was detected within the
cohort of samples that responded well to treatment. It is therefore possible that CYP2E1
expression influences response to treatment.
CYP2E1 induces production of reactive oxygen species [20,25] that may in turn inhibit
reductions of TNFα release by various treatments. All 3 patients in the homozygous reference
haplotype group were high responders to roflumilast plus fluticasone, 5 of 8 patients in the het-
erozygous reference haplotype group were high responders whereas 10 of 14 patients in the
homozygous alternative haplotype group were low responders (Fig 5).
TGF-β and the SMAD signalling pathway have been implicated in the pathology of COPD
[26,27] and lung adenocarcinoma [28,29]. Our results show that genetic variation in the
SMAD gene (rs1065080) may influence response to fluticasone plus roflumilast. Patients that
were deemed to be high responders to roflumilast plus fluticasone exclusively displayed the
homozygous alternative genotype (GG), whereas only 5 of 13 patients in the poor response
group displayed this genotype.
Fig 7. Venn diagram illustrating the overlap between genes that map to SNPs and miRNAs that are associated
with TNFα release from stimulated human lung parenchyma biopsies following roflumilast and fluticasone co-
treatment.
https://doi.org/10.1371/journal.pone.0226564.g007
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Roflumilast has been reported to inhibit TGF-β driven increases in reactive oxygen species
and phosphorylation of SMAD3 by inhibiting TGF-β release [30]. If the genetic variation in
SMAD3 and miRNA expression profile reported in this study alters the functioning of the
pathway then this may help to explain variation in the observed organoculture response. It was
however noted that no common KEGG or GO pathways were found in the bioinformatic con-
gruence analysis.
The AnalytiXagility platform used by partners to share and interrogate the data could
become a powerful resource to both academic researchers and the pharmaceutical industry.
Aridhia’s digital research platform has the potential to link the data generated in this study
with available tissue, DNA and RNA for further research. A platform of this design also offers
the capacity to add patients, analyses and clinical information in real time, thereby tracking
patient outcome and allowing continual remodelling of the data in a secure, version controlled
manner.
With ethical approval, it could be possible for researchers in the pharmaceutical industry to
mine for genetic signatures or other parameters within a target disease area, for the purposes
of patient selection and clinical trial support or for identifying the most appropriate preclinical
model.
The authors acknowledge that while a very high volume of functional and genomics data
was generated, the total number of patients was low for a genomics study and that the statisti-
cal thresholds varied to allow some associations to be made between the data sets. For this rea-
son, the scientific conclusions made from the study remain tentative. The authors do however
feel that this project serves to demonstrate well the potential to explore patient stratification
strategies at a much earlier stage by combining fresh tissue pharmacology, clinical metadata
and genomics.
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